GlassScriptPhysician profile
Cathy L Saunders
NPI 1164424602
$1,356.99
in general payments reported to CMS, 2019-2025
24 companies · $238 in 2025
The $238 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $359 · 2020: $79.89 · 2022: $172 · 2023: $295 · 2024: $213 · 2025: $238.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $556 · Education: $190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $556.08 |
| Education | $189.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $314.58 | 2023-2025 | Veozah, Myrbetriq |
| Meditrina | $125.00 | 2022 | |
| Abbvie INC. | $118.19 | 2019-2023 | Lo Loestrin Fe |
| Ethicon US, LLC | $112.54 | 2019-2024 | Enseal X1, Enseal, Harmonic |
| Mayne Pharma Commercial LLC | $100.11 | 2022-2025 | |
| Lupin INC. | $89.49 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $46.20 | 2020-2023 | Caldolor |
| Duchesnay USA Incorporated | $41.41 | 2019 | |
| Sage Therapeutics, LLC | $38.00 | 2025 | Zurzuvae |
| Pfizer INC. | $36.60 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $36.34 | 2020-2023 | Gardasil 9 |
| Conmed Corporation | $35.57 | 2025 | Airseal |
| Exeltis, USA INC. | $33.56 | 2019-2023 | Slynd |
| Organon LLC | $33.07 | 2024-2025 | Nexplanon |
| Amag Pharmaceuticals, INC. | $31.96 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Pharmaceuticals Incorporated | $23.54 | 2020 | |
| Millicent US INC | $23.18 | 2025 | Intrarosa, Femlyv |
| Supernus Pharmaceuticals, INC. | $21.83 | 2025 | Qelbree |
| Avion Pharmaceuticals | $20.60 | 2019 | |
| Sumitomo Pharma America, INC. | $20.41 | 2025 | Myfembree |
| Covidien LP | $14.78 | 2019 | |
| Hologic Sales and Service, LLC | $14.63 | 2019 | |
| Boston Scientific Corporation | $12.94 | 2019 | |
| Minerva Surgical, INC | $12.46 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cathy Saunders listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.